Navigation Links
Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
Date:8/8/2012

sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Rosetta GenomicsRosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's miRview® product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.Forward-Looking Statement DisclaimerVarious statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the use of proceeds from the offering, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the SEC.  In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by
'/>"/>

SOURCE Rosetta Genomics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
2. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
3. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
4. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
5. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
6. First Plant Genomics Yield Technology Progresses
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
9. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
10. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
11. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
(Date:12/19/2014)... Reports from CDC show ... from one or more chronic health conditions - including ... address some of these diseases, but may not eliminate ... face. While implanted nerve stimulation devices today offer relief, ... which can induce side effects. , To eliminate ...
(Date:12/19/2014)... December 18, 2014 With only 2 ... special on Sartorius Biohit products . The product ... pipettes, Picus Electronic Pipette Trade-in Program, and free pipette ... Safety officers around the world. They are ideal for ... features include:, ,     Full volume range of ...
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... MINNEAPOLIS, Aug. 24, 2011 Cellectis bioresearch, the ... Cellectis (Alternext: ALCLS), and Recombinetics, a specialist in ... development and license agreement on the creation of ... accordance with biosafety and animal well-being requirements, large ...
... Pa., Aug. 24, 2011 Kibow Biotech, Inc. today ... and marketing agreement with the current licensing partner specializing ... 100% natural, probiotic dietary supplement indicated for the reduction ... severe renal failure. Developed by Kibow, Azodyl™ has been ...
... SPRING, Md., Aug. 24, 2011 United Therapeutics ... the completion of its FREEDOM-C(2) Phase 3 trial ... release oral formulation of treprostinil, a stable synthetic ... hypertension (PAH).  Preliminary analysis demonstrates that the trial ...
Cached Biology Technology:Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 3Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... “cautionary tale?about what may go wrong when using the fledgling ... , In the February 16 issue of the Journal of ... M. D. Anderson Cancer Center detail why an experimental test ... of blood is unlikely to lead to a reliable clinical ...
... what may go wrong when using the fledgling science of ... the February 16 issue of the Journal of the National ... Anderson Cancer Center detail why an experimental test intended to ... is unlikely to lead to a reliable clinical test right ...
... of,HIV infection per act of heterosexual sex among a ... have more,than twice the risk of acquiring HIV than ... 15 issue of The Journal of,Infectious Diseases, now available ... Kenya collected detailed sexual data from a,group of male ...
Cached Biology News:Signaling protein builds bigger, better bones in mice 2Signaling protein builds bigger, better bones in mice 3New species from old data 2New species from old data 3Male circumcision reduces risk of HIV transmission from women to men 2
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... Note: Assays in Tris buffer, pH 10.2 ... glycine buffer system. Assays in diethanolamine buffer, ... of the glycine buffer system. Protein determined ... Tris-citrate buffer salts Preparation Unit Definition: One ...
... a wide variety of solvent vapors that can contaminate ... (GCF400) allows for the collection of liquid into a ... minimizes waiting period., Ultra low -104 o ... , Digital Display of temperature ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
Biology Products: